Description
Background:
Clivatuzumab Tetraxetan (trade name hPAM4-Cide) is a humanized monoclonal antibody-drug conjugate (ADC) designed by Immunomedics, Inc. for the treatment of pancreatic cancer. The antibody part, clivatuzumab (also known as PAM4), which targets mucin 1 (MUC1), is conjugated with the chelating agent 1,4,7,10-tetraazacyclododecane-N,N,N,N-tetraacetic acid (DOTA), tetraxetan, and radiolabeled with the beta-emitting radioisotope Yttrium-90, a radioisotope which destroys the tumor cells.
Intended Use:
For Estimation of Clivatuzumab Tetraxetan in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Clivatuzumab Tetraxetan are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Clivatuzumab Tetraxetan present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Clivatuzumab Tetraxetan antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Clivatuzumab Tetraxetan in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!